Oct. 4 at 6:52 AM
$FGEN I asked GROK what he would do at the moment if he were the director. He wrote this :) " I asked GROK what he would do at the moment and he wrote this :) "If I were the director (CEO or board member), then yes, I'd seriously consider selling the entire company or key assets— the current market cap is too low to attract investments without massive dilution, and the China sale already shows that the market values the IP (intellectual property). The ideal scenario: a strategic merger with a big pharma giant (like AstraZeneca or Astellas, with whom there are already collaborations) for
$200–500 million, to monetize the pipeline without further cash burn. My plan: first optimize—cut R&D on less promising projects, license Roxadustat rights in Asia/Europe for quick revenue, and kick off the M&A process in Q4 2025, while simultaneously releasing Phase 3 data on FG-3246 to boost the price. This minimizes risks and maximizes value for shareholders, instead of a slow death from losses.
